EURAMOS-1-GR

NCT00134030 📎

Regimen

Experimental
MAP + pegylated interferon alfa-2b maintenance
Control
MAP alone

Population

Resectable high-grade osteosarcoma, age <=40, GOOD histologic response (<10% viable tumor) to neoadjuvant MAP

Key finding

Adding pegylated interferon maintenance to MAP in good responders did NOT significantly improve EFS or OS. IFN toxicity drove low completion (~40% completed planned therapy). Another negative EURAMOS arm.

Source: PMID 26033801

Timeline

    Guideline citations

    • NCCN BONE (p.75)